Crinetics Pharmaceuticals Reports First Quarter 2022
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated...
Source: globenewswire.com
📰 Ascending Dose Data News
Ascending Dose Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ascending Dose Data. Real-time updates on events, politics, business and more.